MAYNARD, Mass.--(BUSINESS WIRE)--Allegro Diagnostics Corp. today announced that the AEGIS-2 clinical trial has met its primary endpoint, demonstrating that the BronchoGen™ genomic test improves the accuracy of lung cancer diagnosis when used in combination with bronchoscopy. BronchoGen is Allegro Diagnostics’ lead genomic test, and it is built upon the company’s molecular testing platform that utilizes gene expression of cytologically normal epithelial cells in the respiratory tract to aid in the diagnosis of lung cancer. Endpoints in the clinical trial include the sensitivity, specificity and negative predictive value of BronchoGen for identifying patients with malignancy. Complete results from the clinical trial will be submitted for publication in a peer-reviewed journal.
Help employers find you! Check out all the jobs and post your resume.
